Drugs / Unesbulin
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03761095 | Mar 2019 → Feb 2024 | leiomyosarcoma | PTC Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03605550 | Aug 2018 → Mar 2024 overdue | diffuse intrinsic pontine glioma, high grade astrocytic tumor | Nationwide Children's Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03206645 | Aug 2017 → Aug 2021 | ovarian cancer | University of Oklahoma | Completed | No outcome recorded |
| Phase 1 | NCT02404480 | Jan 2016 → Feb 2017 | cancer | PTC Therapeutics | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05269355 | May 2022 → Jun 2024 | leiomyosarcoma | PTC Therapeutics | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Unesbulin | “The goal of this study is to evaluate the safety of the study drug PTC596 (Unesbulin) taken in combination with radiotherapy (RT) when given to pediatric patients newly...” NCT03605550 ↗ |
| Known as | Bmi1 inhibitor ptc596 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594353 ↗ |
| Known as | PTC596 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02404480 ↗ |
| Action | Inhibit | “To test the ability of PTC596 to inhibit BMI-1 activity in tumor and PBMCs” NCT03605550 ↗ |
| Modality | Small molecule | — CHEMBL4594353 ↗ |
| Route | Oral | “administered orally” NCT02404480 ↗ |
| Target | BMI1 | “To test the ability of PTC596 to inhibit BMI-1 activity in tumor and PBMCs” NCT03605550 ↗ |